Karyopharm Therapeutics Stock Technical Analysis

KPTI Stock  USD 1.39  0.09  6.08%   
As of the 28th of March, Karyopharm Therapeutics secures the Risk Adjusted Performance of 0.0928, mean deviation of 6.19, and Downside Deviation of 6.27. Karyopharm Therapeutics technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Strictly speaking, you can use this information to find out if the firm will indeed mirror its model of past prices, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Karyopharm Therapeutics, which can be compared to its peers in the industry. Please verify Karyopharm Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Karyopharm Therapeutics is priced some-what accurately, providing market reflects its recent price of 1.39 per share. Given that Karyopharm Therapeutics is a hitting penny stock territory we strongly suggest to closely look at its total risk alpha.

Karyopharm Therapeutics Momentum Analysis

Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Karyopharm, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to Karyopharm
  
Karyopharm Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.

Karyopharm Therapeutics Analyst Consensus

Target PriceAdvice# of Analysts
6.67Strong Buy7Odds
Karyopharm Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Karyopharm analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Karyopharm stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Karyopharm Therapeutics, talking to its executives and customers, or listening to Karyopharm conference calls.
Karyopharm Analyst Advice Details
Karyopharm Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Karyopharm Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Karyopharm Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Karyopharm Therapeutics Technical Analysis

Indicator
Time Period
Execute Indicator
The output start index for this execution was three with a total number of output elements of fifty-eight. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Karyopharm Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.

Karyopharm Therapeutics Trend Analysis

Use this graph to draw trend lines for Karyopharm Therapeutics. You can use it to identify possible trend reversals for Karyopharm Therapeutics as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Karyopharm Therapeutics price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.

Karyopharm Therapeutics Best Fit Change Line

The following chart estimates an ordinary least squares regression model for Karyopharm Therapeutics applied against its price change over selected period. The best fit line has a slop of   0.01  , which means Karyopharm Therapeutics will continue generating value for investors. It has 122 observation points and a regression sum of squares at 6.38, which is the sum of squared deviations for the predicted Karyopharm Therapeutics price change compared to its average price change.

About Karyopharm Therapeutics Technical Analysis

The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Karyopharm Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Karyopharm Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Karyopharm Therapeutics price pattern first instead of the macroeconomic environment surrounding Karyopharm Therapeutics. By analyzing Karyopharm Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Karyopharm Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Karyopharm Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
 2021 2022 2023 2024 (projected)
Days Of Sales Outstanding39.14109.4267.3952.74
Days Of Inventory Outstanding440.53295.75202.98215.76

Karyopharm Therapeutics March 28, 2024 Technical Indicators

Most technical analysis of Karyopharm help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Karyopharm from various momentum indicators to cycle indicators. When you analyze Karyopharm charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.25)
Revenue Per Share
1.279
Quarterly Revenue Growth
0.005
Return On Assets
(0.27)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.